SGRY Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -4.86% compared to Surgery Partners's net margin of 10.41%. Surgery Partners's return on equity of -5.45% beat Encompass Health's return on equity of 18.4%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 54.27%. On the other hand Encompass Health has an analysts' consensus of $131.58 which suggests that it could grow by 10.4%. Given that Surgery Partners has higher upside potential than Encompass Health, analysts believe Surgery Partners is more attractive than Encompass Health.

Surgery Partners has a beta of 1.931, which suggesting that the stock is 93.143% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.671%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.55% to investors and pays a quarterly dividend of $0.17 per share. Surgery Partners pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Surgery Partners quarterly revenues are $776M, which are smaller than Encompass Health quarterly revenues of $1.5B. Surgery Partners's net income of -$37.7M is lower than Encompass Health's net income of $151.5M. Notably, Surgery Partners's price-to-earnings ratio is -- while Encompass Health's PE ratio is 24.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.81x versus 2.21x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of -4.86% compared to Surgery Partners's net margin of 0.21%. Surgery Partners's return on equity of -5.45% beat LifeStance Health Group's return on equity of -2.48%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 54.27%. On the other hand LifeStance Health Group has an analysts' consensus of $8.86 which suggests that it could grow by 75.74%. Given that LifeStance Health Group has higher upside potential than Surgery Partners, analysts believe LifeStance Health Group is more attractive than Surgery Partners.

Surgery Partners has a beta of 1.931, which suggesting that the stock is 93.143% more volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $776M, which are larger than LifeStance Health Group quarterly revenues of $333M. Surgery Partners's net income of -$37.7M is lower than LifeStance Health Group's net income of $709K. Notably, Surgery Partners's price-to-earnings ratio is -- while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.81x versus 1.50x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

Select Medical Holdings has a net margin of -4.86% compared to Surgery Partners's net margin of 4.19%. Surgery Partners's return on equity of -5.45% beat Select Medical Holdings's return on equity of 8.92%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 54.27%. On the other hand Select Medical Holdings has an analysts' consensus of $20.50 which suggests that it could grow by 39.17%. Given that Surgery Partners has higher upside potential than Select Medical Holdings, analysts believe Surgery Partners is more attractive than Select Medical Holdings.

Surgery Partners has a beta of 1.931, which suggesting that the stock is 93.143% more volatile than S&P 500. In comparison Select Medical Holdings has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.132%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Select Medical Holdings offers a yield of 1.76% to investors and pays a quarterly dividend of $0.06 per share. Surgery Partners pays -- of its earnings as a dividend. Select Medical Holdings pays out 30.19% of its earnings as a dividend. Select Medical Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Surgery Partners quarterly revenues are $776M, which are smaller than Select Medical Holdings quarterly revenues of $1.4B. Surgery Partners's net income of -$37.7M is lower than Select Medical Holdings's net income of $56.7M. Notably, Surgery Partners's price-to-earnings ratio is -- while Select Medical Holdings's PE ratio is 10.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.81x versus 0.39x for Select Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of -4.86% compared to Surgery Partners's net margin of 6.97%. Surgery Partners's return on equity of -5.45% beat US Physical Therapy's return on equity of 4.62%.

Surgery Partners has a consensus price target of $31.36, signalling upside risk potential of 54.27%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 37.06%. Given that Surgery Partners has higher upside potential than US Physical Therapy, analysts believe Surgery Partners is more attractive than US Physical Therapy.

Surgery Partners has a beta of 1.931, which suggesting that the stock is 93.143% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.451, suggesting its more volatile than the S&P 500 by 45.087%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.3% to investors and pays a quarterly dividend of $0.45 per share. Surgery Partners pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

Surgery Partners quarterly revenues are $776M, which are larger than US Physical Therapy quarterly revenues of $183.8M. Surgery Partners's net income of -$37.7M is lower than US Physical Therapy's net income of $12.8M. Notably, Surgery Partners's price-to-earnings ratio is -- while US Physical Therapy's PE ratio is 35.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.81x versus 1.67x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.